Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

NCT00640978 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Significant Adverse Effects - Futility

Conditions

Pancreatic Cancer

Interventions

DRUG: RAD001
DRUG: Erlotinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]